Discovery of an Isothiazole-Based Phenylpropanoic Acid GPR120 Agonist as a Development Candidate for Type 2 Diabetes

被引：23

作者：

Zhang, Xuqing ^{[1
]}

Cai, Chaozhong ^{[1
]}

Sui, Zhihua ^{[1
]}

Macielag, Mark ^{[1
]}

Wang, Yuanping ^{[1
]}

Yan, Wen ^{[1
]}

Suckow, Arthur ^{[1
]}

Hua, Hong ^{[1
]}

Bell, Austin ^{[1
]}

Haug, Peter ^{[1
]}

Clapper, Wilma ^{[1
]}

Jenkinson, Celia ^{[1
]}

Gunnet, Joseph ^{[1
]}

Leonard, James ^{[1
]}

Murray, William V. ^{[1
]}

机构：

[1] Janssen Res & Dev LLC, Cardiovasc & Metab Res, Welsh & McKean Rd,Box 776, Spring House, PA 19477 USA

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2017年 / 8卷 / 09期

关键词：

GPR120; phenylpropanoic acid; type; 2; diabetes; RECEPTOR; 4; FFA4/GPR120; INSULIN-RESISTANCE; FATTY-ACIDS; POTENT; IDENTIFICATION; RODENTS; DESIGN; MICE;

D O I：

10.1021/acsmedchemlett.7b00233

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

We have discovered a novel series of isothiazole-based phenylpropanoic acids as GPR120 agonists. Extensive structure activity relationship studies led to the discovery of a potent GPR120 agonist 4x, which displayed good EC50 values in both calcium and beta-arrestin assays. It also presented good pharmaceutical properties and a favorable PK profile. Moreover, it demonstrated in vivo antidiabetic activity in C57BL/6 DIO mice. Studies in WT and knockout DIO mice showed that it improved glucose handling during an OGTT via GPR120. Overall, 4x possessed promising antidiabetic effect and good safety profile to be a development candidate.

引用

页码：947 / 952

页数：6

共 39 条

[21] Discovery of a liver selective glucokinase activator clinical development candidate for the treatment of Type 2 diabetes
Pfefferkorn, Jeffrey A.
Guzman-Perez, Angel
Litchfield, John
Aiello, Robert
Treadway, Judith L.
Pettersen, John
Minich, Martha L.
Filipski, Kevin J.
Jones, Christopher S.
Tu, Meihua
Aspnes, Gary
Risley, Hud
Wright, Stephen W.
Li, Jian-Cheng
Bian, Jianwei
Benbow, John
Dow, Robert L.
Bourassa, Patricia
D'Aquila, Theresa
Baker, Levenia
Barucci, Nicole
Robertson, Alan
Bourbonais, Francis
Derksen, David R.
MacDougall, Margit
VanVolkenburg, Maria
Cabrera, Over
Chen, Jing
Lapworth, Amanda Lee
Landro, James A.
Atkinson, Karen
Tan, Beijing
Yao, Lili
Kosa, Rachel E.
Haddish-Berhane, Nahor
Feng, Bo
Duignan, David B.
El-Kattan, Ayman
Berliner, Martin A.
Dunetz, Joshua R.
Murdande, Sharad
Liu, Shenping
Ammirati, Mark
Knafels, John
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 241
[22] Preclinical Development of IDG-164177 as a Potent GPR40 Agonist for Treatment of Type 2 Diabetes
Yoon, Jong Min
Kim, Dohee
Lee, Don-Gil
An, Kyung Mi
Lee, Myong Jae
Hong, Chang-Hee
Hong, Dahae
Kwak, Hyun-Jung
Je, In-Gyu
Song, Hyo-Jung
DIABETES, 2020, 69
[23] Discovery of CPL207-280CA, an Effective and Safe GPR40 Agonist for the Treatment of Type 2 Diabetes
Bazydlo, Katarzyna
Buda, Pawel
Mach, Mateusz
Dzida, Radoslaw
Stelmach, Filip
Dubiel, Krzysztof K.
Pieczykolan, Jerzy S.
Wieczorek, Maciej
DIABETES, 2018, 67
[24] Development of IDG-16177, a Selective and Safe GPR40 Agonist for the Treatment of Type 2 Diabetes
Yoon, Jongmin
Song, Haengjin
Kim, Jung Ho
Lee, Seolhee
Shin, Chorong
Jun, Yearin
Hong, Dahae
Lee, Don-Gil
Jang, Eunhye
Kim, Jisu
An, Kyungmi
Hong, Chang-Hee
Kwak, Hyun-Jung
Je, In-Gyu
Song, Hyo-Jung
DIABETES, 2021, 70
[25] A Novel Small-Molecule GPR119 Agonist, HD-0471042, as a Therapeutic Candidate for Type 2 Diabetes Mellitus
Kim, Chun Hwa
DIABETES, 2013, 62 : A675 - A676
[26] Differential Distribution of FFA Receptors, GPR40 and GPR120, in Mouse Islet beta and alpha-Cells May Contribute to Islet Dysfunction in Obesity-Related Type 2 Diabetes.
Lee, S. H.
Sun, J.
Tuo, Y.
Moriyama, Y.
Chen, C.
ENDOCRINE REVIEWS, 2010, 31 (03) : S1651 - S1651
[27] Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes
Christiansen, Elisabeth
Hansen, Steffen V. F.
Urban, Christian
Hudson, Brian D.
Wargent, Edward T.
Grundmann, Manuel
Jenkins, Laura
Zaibi, Mohamed
Stocker, Claire J.
Ullrich, Susanne
Kostenis, Evi
Kassack, Matthias U.
Milligan, Graeme
Cawthorne, Michael A.
Ulven, Trond
ACS MEDICINAL CHEMISTRY LETTERS, 2013, 4 (05): : 441 - 445
[28] Interaction between GPR120 p.R270H loss-of-function variant and dietary fat intake on incident type 2 diabetes risk in the DESIR study
Lamri, A.
Bonnefond, A.
Meyre, D.
Balkau, B.
Roussel, R.
Marre, M.
Froguel, P.
Fumeron, F.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2016, 26 (10) : 931 - 936
[29] Identification of a Promising Drug Candidate for the Treatment of Type 2 Diabetes Based on a P2Y1 Receptor Agonist
Yelovitch, Shir
Barr, Haim M.
Camden, Jean
Weisman, Gary A.
Shai, Ela
Varon, David
Fischer, Bilha
JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (17) : 7623 - 7635
[30] Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes
Shah, Shrenik K.
He, Shuwen
Guo, Liangqin
Quang Truong
Qi, Hongbo
Du, Wu
Lai, Zhong
Liu, Jian
Jian, Tianying
Hong, Qingmei
Dobbelaar, Peter
Ye, Zhixiong
Sherer, Edward
Feng, Zhe
Yu, Yang
Wong, Frederick
Samuel, Koppara
Madiera, Maria
Karanam, Bindhu V.
Reddy, Vijay B.
Mitelman, Stan
Tong, Sharon X.
Chicchi, Gary G.
Tsao, Kwei-Lan
Trusca, Dorina
Feng, Yue
Wu, Margaret
Shao, Qing
Trujillo, Maria E.
Eiermann, George J.
Li, Cai
Pachanski, Michele
Fernandez, Guillermo
Nelson, Donald
Bunting, Patricia
Morissette, Pierre
Volksdorf, Sylvia
Kerr, Janet
Zhang, Bei B.
Howard, Andrew D.
Zhou, Yun-Ping
Pasternak, Alexander
Nargund, Ravi P.
Hagmann, William K.
ACS MEDICINAL CHEMISTRY LETTERS, 2015, 6 (05): : 513 - 517

← 1 2 3 4 →